[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
Krystal Biotech, Inc. Common Stock
Showing only X posts for non-authenticated requests. Use your API key in requests for full results.
"$KRYS $XXXXXX Krystal Biotech skin gene therapy pricing sentiment cautious. 👍 🚀"
X Link @FameInDaMixxx 2025-10-17T04:22Z XX followers, XX engagements
"Health Care Weekly: Corcept Optime Sever Ties; FDA Adverse Event Reports on Compounded Semaglutide; Blumenthal Letter Targets AI in Medicare Advantage; CA Laws on PBMs Private Equity; New 483s h/t @AliceTrace67285 & @dorajfacundo $4568 $6472 $AMRX $CI $CORT $CVS $DSKYF $EHC $ERF.PA $GSK $HIMS $HROW $HUM $KRYS $LLY $LONN $LZAGY $MPLN $NOTV $NVO $OSCR $R $SNY $TEVA $TMO $UNH $VTRS"
X Link @Capitol_Forum 2025-10-16T14:15Z 5983 followers, XXX engagements
"Seven commercial in vivo gene therapies for rare diseases: Luxturna (RPE65-LCA2; $RRHBY) Zolgensma (SMA; $NVS) Kebilidi (AADC deficiency; $PTCT) Roctavian (HemA; $BMRN) Hemgenix (HemB; $QURE) and Elevidys (DMD; $SRPT) using AAV vectors and Vykuvek (DEB; $KRYS) using Herpesvirus. Zolgensma is a blockbuster ($1bn+ net sales/year). Elevidys was on-track to become one (strong demand) despite all the issues associated with systemic gene therapy. Luxturna has had strong demand but so few patients that the commercial case has been very challenging. Vyjuvek did $300M in revenues the first full-year"
X Link @GerardCaelles 2025-10-15T19:56Z 1099 followers, XXX engagements
"FDA platform designation isnt just a label but validates years of Krystals CMG/HSV-1 manufacturing refinement. It confirms reproducibility + scalability letting them leverage KB801. But its really huge when they get aesthetics rolling next year. $KRYS"
X Link @Bernard22190947 2025-10-15T16:57Z XXX followers, XXX engagements